NEW YORK, Jan. 08, 2018 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of INC Research Holdings, Inc. (NASDAQ:INCR) from May 10, 2017 through November 9, 2017, inclusive (the “Class Period”) of the important January 30, 2018 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for INC Research investors under the federal securities laws.
To join the INC Research class action, go to http://rosenlegal.com/cases-1236.html or call Phillip Kim, Esq. or Daniel Sadeh, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, defendants during the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) the merger with inVentiv Health, Inc. (“inVentiv”) was not providing the benefit that Defendants stated it would; (2) inVentiv was underperforming; (3) as a result, INC Research’s 2017 financial performance would be negatively impacted; and (4) as a result of the foregoing, Defendants’ statements about INC Research’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 30, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1236.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Daniel Sadeh, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Daniel Sadeh, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com


xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade
Amazon Explores AI Content Marketplace With Media Publishers
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 



